ArticleTherapeutic advances in medical oncology2022

Plasma tumor mutation burden is associated with clinical benefit in patients with non-small cell lung cancer treated with anti-programmed death-1 monotherapy.

Jii Bum Lee et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.